Table 3.
Univariate and multivariate analysis of prognostic factors in ovarian cancer
| Variable | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | P Value | 95% CI | HR | P Value | 95% CI | |
| Expression of HHLA2 | 0.577 | 0.465 | (0.132,2.523) | 0.156 | 0.049 | (0.025,0.992) |
| Positive vs Negative | ||||||
| Age (years) | 0.711 | 0.522 | (0.250,2.019) | |||
| < 50 vs ≥ 50 | ||||||
| Differentiation | 0.53 | 0.399 | (0.121,2.320) | |||
| Poor and moderate vs well | ||||||
| Pathologic type | 0.439 | 0.275 | (0.100,1.922) | |||
| Serous adenocarcinoma vs other | ||||||
| FIGO Stage | 2.568 | 0.211 | (0.586,11.248) | |||
| I and II vs III and IV | ||||||
| Ascites | 0.275 | 0.211 | (0.036,2.076) | |||
| Positive vs Negative | ||||||
| Vessel | 1.618 | 0.641 | (0.213,12.262) | |||
| Positive vs Negative | ||||||
| Lymph Node | 1.763 | 0.376 | (0.502,6.190) | |||
| Positive vs Negative | ||||||
| Relapse | 1.142 | 0.789 | (0.433,3.011) | |||
| Relapse vs No Relapse | ||||||
| Serum CA125 Before Surgery | 22.49 | 0.469 | (0.005,101,864.851) | |||
| < 35 vs ≥ 35 | ||||||
| Platinum Sensitivity | 4.32 | 0.003 | (1.652,11.294) | 14.14 | 0.002 | (2.632,75.916) |
| Sensitive vs Resistant | ||||||
| CA125 | 1.978 | 0.511 | (0.259,15.137) | |||
| Positive vs Negative | ||||||
| ER | 0.434 | 0.087 | (0.167,1.128) | |||
| Positive vs Negative | ||||||
| PR | 0.328 | 0.028 | (0.121,0.889) | |||
| Positive vs Negative | ||||||
Bold values indicate P < 0.05
ER Estrogen Receptor, PR Progesterone Receptor